Imperial College London, Faculty of Medicine, Department of Surgery and Cancer, Hammersmith Hospital Campus Du Cane Road, London W12 0NN, United Kingdom.
Am J Cancer Res. 2011;1(6):806-16. Epub 2011 Jun 22.
Despite their long recognised pivotal roles in immunological responses, Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are now seen as important players in cancer development and progression. Indeed, mutations in the JAKs are often found in myeloproliferative disorders (MPDs) and leukaemia, and the constitutive phosphorylation of STATs is a common occurrence in many solid and blood cancer cell lines and primary tumour specimens. More recently, we have also shown that JAKs likely have additional roles in promoting drug resistance in several cancer cell types. JAKs and STATs are thus molecules that may serve as useful targets in the clinic. This review will summarise studies that support this notion.
尽管 Janus 激酶 (JAK) 和信号转导与转录激活因子 (STAT) 在免疫反应中的关键作用早已被广泛认可,但现在它们也被认为是癌症发生和发展的重要参与者。事实上,JAK 的突变经常在骨髓增生性疾病 (MPD) 和白血病中发现,STAT 的组成性磷酸化在许多实体瘤和血液癌细胞系以及原发性肿瘤标本中也很常见。最近,我们还表明 JAK 在促进几种癌细胞类型的耐药性方面可能具有额外的作用。因此,JAK 和 STAT 是可能在临床上作为有用靶点的分子。这篇综述将总结支持这一观点的研究。